Recently, Boston Scientific (BSX) added 22 new balloon sizes to its PolarCath Peripheral Dilatation System’s portfolio. The new system with 120 mm and 150 mm balloons are now available in different lengths and sizes.
The PolarCath system is used to treat patients suffering from severe blockages in the arteries below the knee, known as critical limb ischemia, as well as blockages in the femoral and popliteal (behind the knee) arteries. The system helps to restore blood flow in these patients.
The build-up of plaque or lesion in one or more arteries of the legs occurs due to peripheral artery disease. This condition leads to circulatory disorder resulting in a reduction in blood flow through the arteries, consequently causing pain and augmenting the disability. Serious conditions may thus lead us to the last recourse–amputation.
The PolarCath system also provides the advantages of CryoPlasty Therapy for these complex lesions, a new form of balloon angioplasty. Boston Scientific is the only company that offers CryoPlasty Therapy and is thus in an advantageous position to reap the benefits of the therapy through the PolarCath system.
In the first quarter of fiscal 2010, Boston Scientific reported total Peripheral revenue of $165 million, representing an increase of 5% on a year-over-year basis.
Boston Scientific estimates that about 27 million in Europe and North America suffer from the peripheral artery disease. The extension of the PolarCath balloons portfolio within this segment will enable the company to offer more effective and efficient treatment for the disease rather than that achieved through the use of traditional shorter balloons. This will further boost the company’s Peripheral revenue.
Boston Scientific manufactures medical devices and products for use in a broad range of interventional medical specialties. The company faces significant competition across its product portfolio. Primary competitors are Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ).
Presently, we have a ‘Neutral’ recommendation on Boston Scientific.
The build-up of plaque or lesion in one or more arteries of the legs occurs due to peripheral artery disease. This condition leads to circulatory disorder resulting in a reduction in blood flow through the arteries, consequently causing pain and augmenting the disability. Serious conditions may thus lead us to the last recourse–amputation.
The PolarCath system also provides the advantages of CryoPlasty Therapy for these complex lesions, a new form of balloon angioplasty. Boston Scientific is the only company that offers CryoPlasty Therapy and is thus in an advantageous position to reap the benefits of the therapy through the PolarCath system.
In the first quarter of fiscal 2010, Boston Scientific reported total Peripheral revenue of $165 million, representing an increase of 5% on a year-over-year basis.
Boston Scientific estimates that about 27 million in Europe and North America suffer from the peripheral artery disease. The extension of the PolarCath balloons portfolio within this segment will enable the company to offer more effective and efficient treatment for the disease rather than that achieved through the use of traditional shorter balloons. This will further boost the company’s Peripheral revenue.
Boston Scientific manufactures medical devices and products for use in a broad range of interventional medical specialties. The company faces significant competition across its product portfolio. Primary competitors are Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ).
Presently, we have a ‘Neutral’ recommendation on Boston Scientific.
Read the full analyst report on “BSX”
Read the full analyst report on “JNJ”
Read the full analyst report on “MDT”
Read the full analyst report on “STJ”
Read the full analyst report on “ABT”
Zacks Investment Research
